EBOS Leadership Transition

ADMIN
Wed, Feb 19 2025 09:07 am

19 February 2025
NZX/ASX Code: EBO

EBOS Leadership Transition
John Cullity to Retire as CEO; Adam Hall Appointed as Successor

EBOS Group Limited (“EBOS” or “the Group”) today announces that John Cullity will retire as Chief Executive Officer (CEO), effective 30 June 2025. EBOS is also pleased to announce that the Board has appointed Adam Hall as his successor, effective 1 July 2025.

Adam Hall is a highly accomplished global executive with a strong track record in strategic growth, mergers and acquisitions, and operational excellence. Most recently, as Group Executive and President – Asia for Orica Limited, he successfully led significant growth in earnings and scale, while driving innovation and efficiency. Prior to Orica, he held senior executive roles at CF Industries and Bunge in the USA, United Kingdom and Asia.

EBOS Chair, Liz Coutts, said: “We are delighted to appoint Adam as our next CEO. Adam brings deep experience in driving operational efficiency and executing transformative M&A, having led announced transactions worth over US$20 billion in the past decade. His leadership will be instrumental as EBOS continues to pursue its growth ambitions. We look forward to working with him to continue to drive our strong growth and seize new opportunities.”

“John has been a driving force behind EBOS’ success, leading the Group through significant growth. Under his leadership, EBOS has delivered total shareholder returns of 168%, significantly outperforming the market.(1)

“Beyond the results, John has shaped EBOS into the company it is today — expanding our reach, strengthening our businesses across New Zealand, Australia, and Southeast Asia, and positioning us as a leader in healthcare and animal care. On behalf of the Board, I sincerely thank John for his outstanding contribution and wish him the very best in his well-earned retirement.”

Speaking on his appointment, Adam Hall said: “It’s a privilege to join this exceptional team, who have driven EBOS to become a clear leader across the diverse segments in which it operates. EBOS has delivered strong and consistent performance, and I look forward to working with the Board and the Executive Leadership Team to create further growth and innovation in the years ahead.”

Outgoing CEO, John Cullity, said: “My time at EBOS has been an incredible journey. Since joining as CFO in 2009, and later as CEO, I’ve had the privilege of working with exceptional people to grow the Group into what it is today. Over the past decade, we have completed over 20 strategic acquisitions that have strengthened our core businesses while expanding into new sectors, including medical technology.

“I want to extend my gratitude to our Chair, Liz Coutts, the Board, the Executive Leadership Team, and our 5,200 employees across New Zealand, Australia, and Southeast Asia. Their dedication to serving our communities is inspiring, and I am proud of what we have achieved together.”

Incoming CEO Contract
A summary of Adam Hall’s employment contract as incoming CEO is attached. He will be based in Melbourne, Australia.

(1) The TSR calculation uses the NZX share price and NZD dividends and is measured from the closing share price on the last trading day prior to Mr Cullity’s appointment as CEO on 1 April 2018 to the closing share price on 18 February 2025.

For further information please contact:
Investor Relations:
Martin Krauskopf
Executive General Manager, Strategy and Mergers & Acquisitions
+61 3 9918 5555

Media Contacts:
John Bennetts Head of Corporate Affairs and Communications
EBOS Group
+61 498 000 897
[email protected]

Patrick Rasmussen
Public Relations Exchange
+61 430 159 690





Authorised for lodgement with NZX and ASX by the Board of Directors of EBOS Group Limited.

About EBOS Group
EBOS Group Limited NZBN 9429031998840 (NZX/ASX Code: EBO) is the largest and most diversified Australasian marketer, wholesaler and distributor of healthcare, medical and pharmaceutical products. It is also a leading Australasian animal care brand owner, product marketer and distributor.



Announcement PDF


Markets News

The good, the bad, and the ugly of share buybacks
Markets BusinessDesk Explains

The good, the bad, and the ugly of share buybacks

Spark did one, Fletcher did too and now Air NZ is. What are share buy-backs?

Markets Market Close

NZ sharemarket down 1.2% as earnings season hits full swing

The S&P/NZX 50 Index closed at 12.880.36, down 153.00 points or 1.17%.

Gregor Thompson 20 Feb 2025
NZ sharemarket down 1.2% as earnings season hits full swing
Markets

SkyCity just needs a building that’s finished, says CEO

After disappointing results, Jason Walbridge says he's trying to be patient.

Dileepa Fonseka 20 Feb 2025
SkyCity just needs a building that’s finished, says CEO